Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$0.19 | -$0.19 | -$0.19 |
| Q2 2025 | 1 | -$0.20 | -$0.20 | -$0.20 |
| Q3 2025 | 1 | -$0.18 | -$0.18 | -$0.18 |
| Q4 2025 | 1 | -$0.14 | -$0.14 | -$0.14 |
| Q1 2026 | 1 | -$0.13 | -$0.13 | -$0.13 |
| Q2 2026 | 1 | -$0.19 | -$0.19 | -$0.19 |
NanoViricides, Inc. last posted its earnings results on Friday, November 14th, 2025. The company reported $-0.1 earnings per share for the quarter, topping analysts' consensus estimates of $-0.18 by $0.08. The company had revenue of 0 for the quarter and had revenue of 0 for the year. NanoViricides, Inc. has generated $-1 earnings per share over the last year ($-0.63 diluted earnings per share) and currently has a price-to-earnings ratio of -0. NanoViricides, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, December 3rd, 2025 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2025 | Q1 2026 | -$0.18 | -$0.10 | 0.08 | $0 | $0 |
| 09/29/2025 | Q4 2025 | -$0.20 | -$0.13 | 0.07 | $0 | $0 |
| 05/15/2025 | Q3 2025 | -$0.19 | -$0.14 | 0.05 | $0 | $0 |
| 02/14/2025 | Q2 2025 | -$0.18 | -$0.14 | 0.04 | $0 | $0 |
| 11/14/2024 | Q1 2025 | -$0.17 | -$0.23 | -0.06 | $0 | $0 |
| 09/27/2024 | Q4 2024 | -$0.20 | -$0.20 | 0 | $0 | $0 |
| 05/14/2024 | Q3 2024 | -$0.19 | -$0.16 | 0.03 | N/A | $0 |
| 02/14/2024 | Q2 2024 | -$0.19 | -$0.18 | 0.01 | N/A | $0 |
| 11/14/2023 | Q1 2024 | -$0.17 | -$0.17 | 0 | N/A | $0 |
| 10/13/2023 | Q4 2023 | -$0.17 | -$0.31 | -0.14 | N/A | $0 |
| 05/15/2023 | Q3 2023 | -$0.17 | -$0.14 | 0.03 | N/A | $0 |
| 02/14/2023 | Q2 2023 | -$0.16 | -$0.14 | 0.02 | N/A | $0 |
| 11/14/2022 | Q1 2023 | -$0.17 | -$0.13 | 0.04 | N/A | $0 |
| 10/13/2022 | Q4 2022 | -$0.23 | -$0.15 | 0.08 | N/A | $0 |
| 05/16/2022 | Q3 2022 | N/A | -$0.16 | N/A | N/A | $0 |
| 02/14/2022 | Q2 2022 | -$0.22 | -$0.17 | 0.05 | N/A | $0 |
| 11/15/2021 | Q1 2022 | -$0.20 | -$0.23 | -0.03 | N/A | $0 |
| 10/12/2021 | Q4 2021 | N/A | -$0.19 | N/A | N/A | $0 |
| 05/14/2021 | Q3 2021 | N/A | -$0.19 | N/A | N/A | $0 |
| 02/16/2021 | Q2 2021 | N/A | -$0.22 | N/A | N/A | $0 |
NanoViricides, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, December 3rd, 2025 based offlast year's report dates.
In the previous quarter, NanoViricides, Inc. (:NNVC) reported $-0.1 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.18 by $0.08.
The conference call for NanoViricides, Inc.'s latest earnings report can be listened to online.
The conference call transcript for NanoViricides, Inc.'s latest earnings report can be read online.
NanoViricides, Inc. (:NNVC) has a recorded net income of $-9,466,966.NanoViricides, Inc. has generated $-0.63 earnings per share over the last four quarters.
NanoViricides, Inc. (:NNVC) has a price-to-earnings ratio of -0 and price/earnings-to-growth ratio is -0.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED